Home > Neurology > AAN 2019 > Parkinson’s Disease and other Movement Disorders > T-type-calcium channel modulator in essential tremor

T-type-calcium channel modulator in essential tremor

AAN 2019
A randomised study achieved proof-of-concept for CX-8998 in essential tremor. Key pivotal study design parameters including primary and secondary efficacy endpoints, patient population, dose and titration scheme, were identified [1]. Further studies are needed to evaluate its efficacy. CX-8998 is a potent, selective, and state-dependent small molecule modulator of T-type calcium channels. T-type calcium channels play a critical role in the generation of tremor-related oscillations. CX-8998 was evaluated in a double-blind, placebo-controlled study of 95 patients with moderate to severe essential tremor who had inadequate response to standard of care anti-tremor medications. They were randomised to either CX-8998 (titrated to 10 mg BID) or placebo for 28 days. The study's primary endpoint was centrally video-rated TETRAS (The Essential Tremor Rating Assessment Scale) Performance Subscale. Due to methodological issues this endpoint did not reach signif...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on